Larkspur Biosciences to Present New Mechanistic Data on the Role of Pin1 in Modulating the Fibroblast – Cancer Axis at SITC 2023
— Research emphasizes the significant role of Pin1 in influencing critical cancer mechanisms to drive a pro-immune response, reinforcing Pin1 as a promising target for therapeutic interventions
Watertown, MA — October 25, 2023. Larkspur Biosciences, a biotechnology company building precision therapies to outsmart cancer, announced that data supporting development of a novel investigational therapy targeting Pin1 will be featured in a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2023) on November 3 in San Diego, CA. The data look at how the potential therapy will target Pin1 to program fibroblasts to drive a pro-immune response at the tumor.
“Larkspur Biosciences was founded to pursue targets shared by cancer and immune cells that the cancer hijacks to evade immunity. Our data at SITC 2023 demonstrates that Pin1 is a promising cancer–fibroblast target to pursue for therapeutic interventions,” said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. “Standard of care immunotherapy has revolutionized cancer treatment, but less than 30 percent of patients respond. At Larkspur, we believe there is an opportunity to leverage targets shared by both the cancer and the immune system as a more effective way to activate the immune system against cancer.”
Poster: Abstract 1433
Title: “Targeting peptidyl-prolyl isomerase Pin1 to modulate cancer-associated fibroblast phenotype and TGF-beta signaling ”
Time: Friday, November 3, 12-1:30pm and 5:10-6:40pm PT
Location: San Diego Convention Center, Exhibit Halls A and B1
Presenter: Melvyn Chow, PhD, Associate Director, Biology, Larkspur Biosciences
About Larkspur Biosciences
Larkspur Biosciences is building precision therapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by using pathways shared by cancer and immune cells, developing precision therapies for molecularly defined patient populations in order to overcome these bottlenecks. The company is advancing its first-in-class programs to outsmart the tumor and enable robust and sustained responses in colorectal cancer (CRC) and beyond. LarkX, the company’s target discovery platform, leverages tumor genetics from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer. Visit us at www.larkspur.bio and follow us on LinkedIn and X.